U.S. markets closed

Biocept, Inc. (BIOC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.4400-0.1100 (-2.42%)
At close: 4:00PM EDT

4.4300 -0.01 (-0.23%)
After hours: 5:41PM EDT

Sign in to post a message.
  • k
    kevin
    @Danny
    You mentioned accumulating on BLSP. Would you mind sharing what’s going on with that? Thanks!
  • A
    Amitaba
    I don’t pump - just stating the fact. The testing demand is going to prolong and increase due to the risk attention enveloping international cross border biohazard security. I do not think this scenario can be ignored.
    I recalled just one shoe bomber had caused us to remove our shoes during custom screening.
    Covid 19 at this moment we still cannot pin down patient zero but just some scapebat.

    Vaccines or negative testing passport is a sign of deterrence in that direction in international travel

    Bioc could get a handsome testing revenue for long time.
  • A
    Amitaba
    Jessica - I invest in real business with real revenue production with long term future growth. I don’t invest in hope and most Biotech are such with zero revenue
  • T
    TheExpendables
    No matter how good the news,blow out earnings,product launches,number of covid tests etc...this stock goes no where.There is no explanation other then no confidence in current CEO by wallstreet.If he would resign and a proven and trusted person took over this stock would probably go over $100 a share.
  • T
    TheExpendables
    After nothing but good news including a great earnings report I am convinced there are only 2 ways to get BIOC stock to go up,either they get bought out or Nail resigns and they hire a professional CEO that wallstreet big money will trust and get behind.Until then it just seems we are doomed to stay the same course forever.
  • T
    TheExpendables
    Danny if your not in it is not to late to hop in OCGN,explosive move is coming.
  • A
    Amitaba
    USA address in UN about next pandemic prevention is a clear mechanism of inter country biohazard deterrence platform. So testing is going to be huge. VeeSure is going to be in huge demand
  • A
    Alonso
    Michael Nall is Amitaba?
  • T
    TheExpendables
    Short interest is only at 5.78% so that is not enough to move this stock by a short squeeze.It will take real news like a buyout to move this stock.
  • s
    san
    Amitaba with all the data , information , statistics for the past 6 months you have been presenting on this forum not sure the source of this 🙄 the stock is not moving at all and if it is , only downward ?don’t you think you should take a break my friend and let the stock take its natural course - saving you some stress
  • J
    Jessica
    This stock is being controlled/manipulated by the MMs. They are making their money off of the retailers. Just watch the large caps in the bid and asks that ensure they control the spread. They walk it up when they want and walk it down. 4Q mirrored 3Q.

    Even though all the retailers lose their shirts, the Institutions are still up on this stock (hence the >$5 bottom where are now versus the $4.5 where they bought (or back) in)...and BIOC gets what they need to stay alive by keeping the price down so they have buyers for more shares when they need it undoubtedly coming in Q2 if they can get a buyer for $5.50 or higher...knowing they will have another decent 1Q earnings to protect the bottom.

    Until they start showing oncology testing/rev again, no chance this takes off.

    Still, sitting on ~$30m in cash and what appears to be a consistent >$12+m in revenue each quarter this year...no debt, and still low overhead... the financials should have this trading >$10.

    Would be great to see someone here comment on the financials and lack of oncology testing as their basis to help the retailers on here. I just chime in to at my 2 cents.
  • T
    TheExpendables
    Amitaba If you want to watch a real short squeeze unfold start keeping an eye on OCGN.Last 6 days on heavy volume share price has been increasing but short volume has averaged over 30% of the volume over these days.Cramer on Madmoney said a good speculative play with a heavy short interest.This could be next GME in the making if they really try to force a squeeze out.Even if you don't buy in keep an eye on it should be interesting to watch.I'm in OCGN for a coupole thousand shares now.
  • T
    TheExpendables
    I have been here holding long for quite sometime.My biggest criticism has always been with the CEO.He doesn't know how to sell and market the BIOC.I believe this drop after a great earnings results is due to lack of confidence in the CEO given his past track record.Plain and simple big institutions do not trust him and if he would just step aside and hire a respected CEO this stock would skyrocket.He may be a smart guy and very knowledgeable but that doesn't make him qualified to be a good CEO and his way of delivering the companies message to gain excitement and get big institutions onboard is simply failing.
    Bullish
  • A
    Amitaba
    Cancer early detection - it is more appropriate to call precancerous liquid based genome profiling instead of liquid biopsy. I can see the AI and data acquisition that goes to help the adoption of such diagnostic platform. It is coming of age in human digital health status information and preventive care

    Biocept carry a powerful IP
  • A
    Amitaba
    Bioc is losing a golden opportunity if they do not look at research of vaccines for coronavirus with the 350,000 test samples processed. In a research lab, One bat do not give you that amount of virus and variants to study.

    Never say never.
  • R
    Ramiro
    Massive manipulation by MM! They will keep playing with the price for their gains in the near future. Super undervalued at $4.28 with 250% upside potential in the next 3 months.
    Bullish
  • M
    Mothra
    I?m out - sold this #$%$ for a $6K loss. Will make it up elsewhere. Goodbye and good riddens...Ami Blah Blah Blah.
  • A
    Amitaba
    I fully disagree. The stock unresponsive to good news is not about the good news. I would say a great percentage of holders average cost basis are very low $3 to $8 but their expectations is $ 60 to $80.
    Nobody is willing to give up any near term gain. The thin volume is day traders and shorts try to cycle the game.

    Covid test should be a long term base load for Bioc. Liquid biopsy is going to be huge with early target cancer screening paid by Medicare for senior from age 60 and eligible patient with cancer genetic makeup, etc
  • T
    TheExpendables
    Amitaba, Mike Nail is a scientist not a CEO,there is a reason many companies that are successful hire professional successful CEO to lead their companies because they know how to sell the company to wall street to bring in big money and investments to help the company grow.Nail only knows how to issue shares to fund operations because he can't get wall street on board.No doubt a different CEO would be viewed positively by wall street.
  • d
    dolcini
    They had some interesting insights about BIOC on (http://Stocks-tracker.com). Definitely made me think twice about the company.